The oncogenic role of LGR6 overexpression induced by aberrant Wnt/ β‐catenin signaling in lung cancer
ConclusionsOur findings highlight the oncogenic roles of LGR6 overexpression induced by aberrant Wnt/ β-catenin signaling in lung cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 28, 2023 Category: Cancer & Oncology Authors: Noriaki Sunaga,
Kyoichi Kaira,
Kimihiro Shimizu,
Ichidai Tanaka,
Yosuke Miura,
Seshiru Nakazawa,
Yoichi Ohtaki,
Reika Kawabata ‐Iwakawa,
Mitsuo Sato,
Luc Girard,
John D. Minna,
Takeshi Hisada Tags: ORIGINAL ARTICLE Source Type: research
Segmentectomy quality remains important in ground ‐glass‐dominant stage I lung cancer
ConclusionAnatomical segmentectomy resulted in better survival and a lower incidence of thick lung plication, even in GGO-dominant tumors. Therefore, further standardization and quality management of segmentectomy procedures will improve the clinical outcomes. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 28, 2023 Category: Cancer & Oncology Authors: Wongi Woo,
Jimin Lee,
Dae Hyun Jin,
Jihoon Kim,
Duk Hwan Moon,
Sungsoo Lee Tags: ORIGINAL ARTICLE Source Type: research
Extended ICI treatment after first ‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)
ConclusionExtended ICI treatment after chemoimmunotherapy and maintenance therapy enhanced the efficacy of second-line RD treatment in patients with advanced NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 28, 2023 Category: Cancer & Oncology Authors: Ou Yamaguchi,
Keita Mori,
Saori Takata,
Kazuhiko Shibata,
Kenichi Chikamori,
Nozomu Kimura,
Yoshiaki Nagai,
Taku Nakagawa,
Satoshi Igawa,
Taishi Harada,
Hiroshige Yoshioka,
Hisashi Tanaka,
Hitomi Nogawa,
Hiroaki Satoh,
Toshihiro Shiozawa,
K Tags: ORIGINAL ARTICLE Source Type: research
Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study
ConclusionThe findings suggest that small molecule multitarget antiangiogenic inhibitors are efficacious as second or post-line treatments as a viable alternative treatment option for patients with advanced TETs. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Wanji Shen,
Ying Jin,
Ying Yu,
Ning Chen,
Yun Fan Tags: ORIGINAL ARTICLE Source Type: research
Kristen rat sarcoma virus (KRAS) G12F ‐positive non‐small cell lung cancer mimicking KRAS G12C positivity: A case report
In this report, we describe a case in which a positive result for Kristen rat sarcoma virus (KRAS) exon2 p.G12F, a rareKRAS mutation, may have led to a false-positive result forKRAS exon2 p.G12C on AMOY. Genetic analysis in this case was performed by LC-SCRUM-Asia. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Issei Oi,
Takanori Ito,
Zentaro Saito,
Takuma Imakita,
Osamu Kanai,
Kohei Fujita,
Hiromasa Tachibana,
Tadashi Mio Tags: CASE REPORT Source Type: research
Single ‐cell RNA sequencing reveals immune microenvironment of small cell lung cancer‐associated malignant pleural effusion
We use 10 × genomics single-cell transcriptome sequencing technology to reveal the tumor immune microenvironment characteristics of small cell lung cancer (SCLC) in malignant pleural effusion (MPE). A total of 8008 high-quality cells were obtained and divided as B cells, T cells, myeloid cells, NK cells , and cancer cells (a). Such SCLC related genes as NOTCH1, MYC, TSC22D1, SOX4, BLNK, YBX3, VIM, CD8A, CD8B, and KLF6 were expressed in different degrees during differentiation of CD4+ T cells (b), CD8+ T cells (c), and B cells (d). Different ligands and receptors between T, B, and tumor cells almost interact through M...
Source: Thoracic Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Shuyan Wang,
Jing An,
Xueru Hu,
Tingting Zeng,
Ping Li,
Jiangyue Qin,
Yongchun Shen,
Mei Chen,
Fuqiang Wen Tags: CASE REPORT Source Type: research
Association of antibiotic exposure with survival in patients with extensive ‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy
ConclusionsOur results demonstrate that ATB exposure was significantly associated with worse survival in ES-SCLC patients who received ICI therapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Jiaqi Zhong,
Dali Xiong,
Yu Liu,
Shuanghu Yuan Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - November 24, 2023 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Gentiana macrophylla flavonoids from Tibetan medicine decreases circ_0059665 to alleviate the progression of non ‐small cell lung cancer under hypoxia
ConclusionGF treatment in hypoxic environments suppressed NSCLC cell proliferation, invasion and M2 macrophage polarization via the circ_0059665/miR-512-5p/NOVA2 axis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 23, 2023 Category: Cancer & Oncology Authors: Mi Ma,
Dunzhu Ciren,
Mingke Feng,
Luo Zhen,
Guilin Jin Tags: ORIGINAL ARTICLE Source Type: research
Circ_0020123 promotes non ‐small cell lung cancer progression via miR‐146a‐5p mediated regulation of EIF4G2 expression
ConclusionKnockdown of circ_0020123 inhibited NSCLC cell progression and tumor growth by targeting the miR-146a-5p/EIF4G2 axis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 23, 2023 Category: Cancer & Oncology Authors: Zichun Wei,
Jixian Liu,
Gang Hui,
Xinyu Luan Tags: ORIGINAL ARTICLE Source Type: research
Observed and relative survival trends of lung cancer: A systematic review of population ‐based cancer registration data
ConclusionOver the past decades, the prognosis of lung cancer has gradually improved, but significant variations were also observed globally. Worldwide, a better prognosis of lung cancer can be observed in females and younger patients. It is essential to compare and evaluate the histological or stage-specific survival rates of lung cancer between different regions in the future. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 21, 2023 Category: Cancer & Oncology Authors: Jing ‐Hao Bi,
Jia‐Yi Tuo,
Yu‐Xuan Xiao,
Dan‐Dan Tang,
Xiao‐Hui Zhou,
Yu‐Fei Jiang,
Xiao‐Wei Ji,
Yu‐Ting Tan,
Hui‐Yun Yuan,
Yong‐Bing Xiang Tags: ORIGINAL ARTICLE Source Type: research
Exploring readiness for discharge, quality of discharge teaching, and fear of disease progression in lung cancer patients undergoing chemotherapy: A correlation analysis
ConclusionDischarge readiness among patients with lung cancer receiving chemotherapy was relatively at the good level, and there was a significant correlation between readiness for discharge, discharge teaching and fear of disease progression in these patients. Therefore, it is necessary to provide effective discharge guidance and implement targeted intervention measures to further improve patient preparation, reduce the fear of disease progression, and promote patient ability of coping with the disease and overall satisfaction. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 21, 2023 Category: Cancer & Oncology Authors: Yan Wang,
Jinping Li,
Minfeng Zhai,
Yang Zhao,
Qiuyue Li Tags: ORIGINAL ARTICLE Source Type: research
Long ‐term follow‐up of unresectable adenoid cystic carcinoma of the trachea and bronchus treated with high‐dose proton beam therapy: A report of two cases
This report showed two cases of unresectable adenoid cystic carcinoma of the trachea and bronchus that received definitive proton beam therapy with concurrent chemotherapy. Proton beam therapy can deliver high doses (74 Gy [relative biological effectiveness]) safely to unresectable adenoid cystic carcinoma tumors and may contribute to long-term local control and overall survival. AbstractAdenoid cystic carcinoma (ACC) of the trachea is a rare disease that is slow growing and has a risk of distant metastasis. The standard treatment for ACC of the trachea is surgery, but this tumor is often unresectable. In definitive rad...
Source: Thoracic Cancer - November 21, 2023 Category: Cancer & Oncology Authors: Masatoshi Nakamura,
Kayoko Ohnishi,
Kensuke Nakazawa,
Kei Shimizu,
Daigo Miyauchi,
Masashi Mizumoto,
Kei Nakai,
Toshiyuki Okumura,
Hideyuki Sakurai Tags: CASE REPORT Source Type: research
Robust imaging approach for precise prediction of postoperative lung function in lung cancer patients prior to curative operation
ConclusionsUse of DECT image processing to predict postoperative lung function produced better agreement with actual postoperative lung function than conventional methods. The combined variable method produced ICC values of 0.8 or greater for FVC and FEV1. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 16, 2023 Category: Cancer & Oncology Authors: Suho Kim,
Jonghoon Kim,
Uichan Jeong,
You Jin Oh,
Sung Goo Park,
Ho Yun Lee Tags: ORIGINAL ARTICLE Source Type: research
Investigation of response of patients with non ‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment
ConclusionsOur results suggest that DTX and DTX + RAM therapies immediately after treatment with ICI-containing regimens as well as continuation of DTX without dose reduction after the second cycle may increase the response rate and prolong survival in patients with NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 15, 2023 Category: Cancer & Oncology Authors: Yutaka Takahara,
Ryudai Abe,
Sumito Nagae,
Takuya Tanaka,
Yoko Ishige,
Ikuyo Shionoya,
Kouichi Yamamura,
Kazuaki Nishiki,
Masafumi Nojiri,
Ryo Kato,
Shohei Shinomiya,
Taku Oikawa Tags: ORIGINAL ARTICLE Source Type: research
